The present study aimed to formulate and evaluate a pharmaceutical study on formulating and characterising immediate - release tablets of Sevelamer carbonate, a non - absorbable phosphate binder used to treat hyperphosphatemia in chronic kidney disease patient s.Six formulations (F1 - F6) were developed using wet granulation with varying super disintegrants like cross - povidone and croscarmellose sodium, alongside excipients such as microcrystalline cellulose, magnesium stearate, and talc, followed by comprehensive pre - formulation, compression, and quality control evaluations, including FTIR compatibility, flow properties, weight variation, hardness, friability, disintegration, dissolution, and stability testing. Key findings highlight good powder flow (e.g., bulk d ensity 0.714 g/ml, Hausner's ratio 1.16), tablet quality within USP limits (friability 0.79%, disintegration ~2.18 min), and optimal drug release up to 82.56% at 90 minutes for F3, confirming suitability for rapid phosphate binding without drug - excipient i nteractions or stability issues over tested periods.